PL355101A1 - Zastosowanie antagonisty H 1 i bezpiecznego steroidu do leczenia chorób oczu - Google Patents

Zastosowanie antagonisty H 1 i bezpiecznego steroidu do leczenia chorób oczu

Info

Publication number
PL355101A1
PL355101A1 PL00355101A PL35510100A PL355101A1 PL 355101 A1 PL355101 A1 PL 355101A1 PL 00355101 A PL00355101 A PL 00355101A PL 35510100 A PL35510100 A PL 35510100A PL 355101 A1 PL355101 A1 PL 355101A1
Authority
PL
Poland
Application number
PL00355101A
Other languages
English (en)
Inventor
John M. Yanni
Original Assignee
Alcon Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc. filed Critical Alcon Inc.
Publication of PL355101A1 publication Critical patent/PL355101A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL00355101A 1999-11-18 2000-10-26 Zastosowanie antagonisty H 1 i bezpiecznego steroidu do leczenia chorób oczu PL355101A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16619499P 1999-11-18 1999-11-18
PCT/US2000/029436 WO2001035963A1 (en) 1999-11-18 2000-10-26 Use of h1 antagonist and a safe steroid to treat eye conditions

Publications (1)

Publication Number Publication Date
PL355101A1 true PL355101A1 (pl) 2004-04-05

Family

ID=22602196

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355101A PL355101A1 (pl) 1999-11-18 2000-10-26 Zastosowanie antagonisty H 1 i bezpiecznego steroidu do leczenia chorób oczu

Country Status (12)

Country Link
US (1) US6649602B1 (pl)
EP (1) EP1242090A4 (pl)
CN (1) CN1376066A (pl)
AU (1) AU772406B2 (pl)
BR (1) BR0015647A (pl)
CA (1) CA2380532A1 (pl)
HK (1) HK1047699A1 (pl)
MX (1) MXPA02005007A (pl)
PL (1) PL355101A1 (pl)
TR (1) TR200201322T2 (pl)
WO (1) WO2001035963A1 (pl)
ZA (1) ZA200201903B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
DK1467762T3 (da) * 2001-12-05 2006-04-10 Alcon Inc Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
CN1674916A (zh) 2002-08-30 2005-09-28 奥坦纳医药公司 环缩松与抗组胺药的组合用于治疗变应性鼻炎的用途
PL376970A1 (pl) * 2002-11-12 2006-01-23 Alcon, Inc. Zastosowanie środka przeciwalergicznego i steroidu do leczenia alergicznego nieżytu nosa
EP1591110B1 (en) * 2003-01-22 2015-03-18 Senju Pharmaceutical Co., Ltd. Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
JP4980226B2 (ja) * 2004-10-25 2012-07-18 ボーシュ アンド ローム インコーポレイティド 眼科用組成物及びその使用方法
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
DK2522365T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
WO2006097458A1 (en) * 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
CA2661197C (en) * 2006-09-11 2012-01-03 Bausch & Lomb Incorporated Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
WO2009067317A2 (en) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Use of levocabastine for modulating generation of pro- inflammatory cytokines
US20100240624A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
EP3943069A1 (en) 2009-03-17 2022-01-26 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US20130023520A1 (en) * 2011-07-24 2013-01-24 Amir Sahba Jalali Anaesthetic eye solution and method of use
WO2013061269A1 (en) * 2011-10-26 2013-05-02 Micro Labs Limited Combinations of loteprednol and olopatadine for the treatment of ocular allergies
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US5149694A (en) 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and dexamethasone for topical ophthalmic use
US5192780A (en) 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US5668133A (en) * 1992-12-09 1997-09-16 Alcon Laboratories, Inc. Ophthalmic compositions comprising emedastine and methods for their use
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use

Also Published As

Publication number Publication date
CN1376066A (zh) 2002-10-23
CA2380532A1 (en) 2001-05-25
TR200201322T2 (tr) 2002-11-21
WO2001035963A1 (en) 2001-05-25
US6649602B1 (en) 2003-11-18
ZA200201903B (en) 2003-05-28
EP1242090A4 (en) 2004-02-11
AU4610101A (en) 2001-05-30
AU772406B2 (en) 2004-04-29
MXPA02005007A (es) 2004-08-12
EP1242090A1 (en) 2002-09-25
HK1047699A1 (zh) 2003-03-07
BR0015647A (pt) 2002-07-16

Similar Documents

Publication Publication Date Title
PL355101A1 (pl) Zastosowanie antagonisty H 1 i bezpiecznego steroidu do leczenia chorób oczu
GB9913536D0 (en) Use
IL145995A0 (en) Use
GB9900227D0 (en) Use of a composition
EG22530A (en) Preparation of substituted piperidin-4-ones
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9919971D0 (en) Use
GB9929772D0 (en) New use
HUP0202614A3 (en) Use of thienopyrimidines
GB9911238D0 (en) Therapeutic use
GB9910667D0 (en) New use of citreamicins
GB9921062D0 (en) Use of cholestrol-lowering agent
EP1230928A4 (en) USE OF PEPTIDE
GB9920242D0 (en) Swab
TW468411U (en) Structure of cardcase
TW394123U (en) Structure of emery-roller
TW389046U (en) Structure of hairgrip combinations
HU9900075V0 (en) Sepulchre consists of elements
GB9910166D0 (en) Use
CA88062S (en) Set of cutlery
CA87150S (en) Set of cutlery
GB9909843D0 (en) Compounds and their use
GB9930100D0 (en) New use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)